Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
SRDX's Cash to Debt is ranked higher than
86% of the 254 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.82 vs. SRDX: No Debt )
SRDX' s 10-Year Cash to Debt Range
Min: No Debt   Max: No Debt
Current: No Debt

Equity to Asset 0.94
SRDX's Equity to Asset is ranked higher than
97% of the 234 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.63 vs. SRDX: 0.94 )
SRDX' s 10-Year Equity to Asset Range
Min: 0.74   Max: 0.95
Current: 0.94

0.74
0.95
Interest Coverage No Debt
SRDX's Interest Coverage is ranked higher than
97% of the 143 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 62.48 vs. SRDX: No Debt )
SRDX' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 7
Z-Score: 30.20
M-Score: -2.85
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 32.34
SRDX's Operating margin (%) is ranked higher than
99% of the 251 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.33 vs. SRDX: 32.34 )
SRDX' s 10-Year Operating margin (%) Range
Min: -25.85   Max: 51.75
Current: 32.34

-25.85
51.75
Net-margin (%) 20.95
SRDX's Net-margin (%) is ranked higher than
98% of the 251 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.44 vs. SRDX: 20.95 )
SRDX' s 10-Year Net-margin (%) Range
Min: -30.17   Max: 32.59
Current: 20.95

-30.17
32.59
ROE (%) 12.89
SRDX's ROE (%) is ranked higher than
87% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.21 vs. SRDX: 12.89 )
SRDX' s 10-Year ROE (%) Range
Min: -12.91   Max: 23.9
Current: 12.89

-12.91
23.9
ROA (%) 12.07
SRDX's ROA (%) is ranked higher than
95% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.22 vs. SRDX: 12.07 )
SRDX' s 10-Year ROA (%) Range
Min: -11.85   Max: 19.94
Current: 12.07

-11.85
19.94
ROC (Joel Greenblatt) (%) 102.26
SRDX's ROC (Joel Greenblatt) (%) is ranked higher than
96% of the 255 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. SRDX: 102.26 )
SRDX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -27.6   Max: 154.38
Current: 102.26

-27.6
154.38
Revenue Growth (%) 2.20
SRDX's Revenue Growth (%) is ranked higher than
68% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. SRDX: 2.20 )
SRDX' s 10-Year Revenue Growth (%) Range
Min: -24.6   Max: 57.8
Current: 2.2

-24.6
57.8
EPS Growth (%) 11.80
SRDX's EPS Growth (%) is ranked higher than
84% of the 167 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.30 vs. SRDX: 11.80 )
SRDX' s 10-Year EPS Growth (%) Range
Min: -35.4   Max: 46.8
Current: 11.8

-35.4
46.8
» SRDX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

SRDX Guru Trades in Q4 2013

Mario Gabelli 15,617 sh (New)
Jim Simons 455,138 sh (+6.91%)
Chuck Royce 733,300 sh (unchged)
Steven Cohen Sold Out
Bill Frels 745,690 sh (-0.65%)
Joel Greenblatt 46,744 sh (-14.87%)
» More
Q1 2014

SRDX Guru Trades in Q1 2014

Mario Gabelli 33,300 sh (+113.23%)
Jim Simons 510,395 sh (+12.14%)
Chuck Royce 733,300 sh (unchged)
Joel Greenblatt Sold Out
Bill Frels 739,540 sh (-0.82%)
» More
Q2 2014

SRDX Guru Trades in Q2 2014

Mario Gabelli 130,778 sh (+292.73%)
Chuck Royce 744,800 sh (+1.57%)
Bill Frels 738,470 sh (-0.14%)
Jim Simons 504,238 sh (-1.21%)
» More
Q3 2014

SRDX Guru Trades in Q3 2014

Mario Gabelli 185,398 sh (+41.77%)
Chuck Royce 744,800 sh (unchged)
Jim Simons 501,938 sh (-0.46%)
Bill Frels 728,390 sh (-1.36%)
» More
» Details

Insider Trades

Latest Guru Trades with SRDX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Mario Gabelli 2014-09-30 Add 41.77%0.01%$18.12 - $22.4 $ 21.437%185398
Mario Gabelli 2014-06-30 Add 292.73%0.01%$19.85 - $23.37 $ 21.430%130778
Joel Greenblatt 2014-03-31 Sold Out 0.03%$22.14 - $25.79 $ 21.43-12%0
Mario Gabelli 2014-03-31 Add 113.23%$22.14 - $25.79 $ 21.43-12%33300
Mario Gabelli 2013-12-31 New Buy$21.61 - $25.135 $ 21.43-9%15617
Joel Greenblatt 2013-06-30 Add 38.66%0.01%$19.74 - $27.55 $ 21.43-14%59954
Joel Greenblatt 2012-12-31 Reduce -25.79%0.03%$17.45 - $22.03 $ 21.438%53262
Joel Greenblatt 2012-12-31 Reduce -25.79%0.03%$17.45 - $22.03 $ 21.438%53262
Joel Greenblatt 2012-09-30 Add 60.21%0.04%$15.38 - $20.78 $ 21.4319%71768
Mario Gabelli 2012-09-30 Sold Out 0.03%$15.38 - $20.78 $ 21.4319%0
PRIMECAP Management 2012-06-30 Sold Out 0.0015%$13.6 - $17.22 $ 21.4343%0
Joel Greenblatt 2012-03-31 Add 200.69%0.04%$13.86 - $16.06 $ 21.4356%44610
Richard Snow 2012-03-31 Sold Out 0.02%$13.86 - $16.06 $ 21.4356%0
Joel Greenblatt 2011-12-31 New Buy0.03%$8.86 - $14.99 $ 21.4388%14836
Richard Snow 2011-12-31 Add 48.24%0.01%$8.86 - $14.99 $ 21.4388%24659
PRIMECAP Management 2011-12-31 Reduce -73.57%$8.86 - $14.99 $ 21.4388%66000
Richard Snow 2011-09-30 Reduce -35.59%$8.99 - $12.06 $ 21.43103%16634
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 24.60
SRDX's P/E(ttm) is ranked higher than
89% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. SRDX: 24.60 )
SRDX' s 10-Year P/E(ttm) Range
Min: 8.5   Max: 687.94
Current: 24.6

8.5
687.94
P/B 2.95
SRDX's P/B is ranked higher than
79% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.46 vs. SRDX: 2.95 )
SRDX' s 10-Year P/B Range
Min: 0.98   Max: 7.77
Current: 2.95

0.98
7.77
P/S 5.18
SRDX's P/S is ranked higher than
67% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.11 vs. SRDX: 5.18 )
SRDX' s 10-Year P/S Range
Min: 2.16   Max: 13.8
Current: 5.18

2.16
13.8
PFCF 18.16
SRDX's PFCF is ranked higher than
95% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. SRDX: 18.16 )
SRDX' s 10-Year PFCF Range
Min: 9.43   Max: 511.5
Current: 18.16

9.43
511.5
EV-to-EBIT 13.18
SRDX's EV-to-EBIT is ranked higher than
93% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. SRDX: 13.18 )
SRDX' s 10-Year EV-to-EBIT Range
Min: -47.4   Max: 253.6
Current: 13.18

-47.4
253.6
Shiller P/E 51.66
SRDX's Shiller P/E is ranked higher than
88% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. SRDX: 51.66 )
SRDX' s 10-Year Shiller P/E Range
Min: 16.9   Max: 158.8
Current: 51.66

16.9
158.8
Current Ratio 13.59
SRDX's Current Ratio is ranked higher than
96% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.56 vs. SRDX: 13.59 )
SRDX' s 10-Year Current Ratio Range
Min: 1.77   Max: 13.59
Current: 13.59

1.77
13.59
Quick Ratio 12.90
SRDX's Quick Ratio is ranked higher than
96% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.16 vs. SRDX: 12.90 )
SRDX' s 10-Year Quick Ratio Range
Min: 1.69   Max: 12.9
Current: 12.9

1.69
12.9

Valuation & Return

vs
industry
vs
history
Price/Net Cash 7.22
SRDX's Price/Net Cash is ranked higher than
91% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. SRDX: 7.22 )
SRDX' s 10-Year Price/Net Cash Range
Min: 6.3   Max: 107.95
Current: 7.22

6.3
107.95
Price/Net Current Asset Value 6.41
SRDX's Price/Net Current Asset Value is ranked higher than
90% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. SRDX: 6.41 )
SRDX' s 10-Year Price/Net Current Asset Value Range
Min: 5.52   Max: 206.38
Current: 6.41

5.52
206.38
Price/Tangible Book 2.96
SRDX's Price/Tangible Book is ranked higher than
86% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.28 vs. SRDX: 2.96 )
SRDX' s 10-Year Price/Tangible Book Range
Min: 1.26   Max: 12
Current: 2.96

1.26
12
Price/DCF (Projected) 1.47
SRDX's Price/DCF (Projected) is ranked higher than
94% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. SRDX: 1.47 )
SRDX' s 10-Year Price/DCF (Projected) Range
Min: 0.53   Max: 4.59
Current: 1.47

0.53
4.59
Price/Median PS Value 0.80
SRDX's Price/Median PS Value is ranked higher than
92% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.36 vs. SRDX: 0.80 )
SRDX' s 10-Year Price/Median PS Value Range
Min: 0.36   Max: 4.91
Current: 0.8

0.36
4.91
Price/Graham Number 1.78
SRDX's Price/Graham Number is ranked higher than
94% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. SRDX: 1.78 )
SRDX' s 10-Year Price/Graham Number Range
Min: 1.28   Max: 10.34
Current: 1.78

1.28
10.34
Earnings Yield (Greenblatt) 7.60
SRDX's Earnings Yield (Greenblatt) is ranked higher than
92% of the 248 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.80 vs. SRDX: 7.60 )
SRDX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.4   Max: 22
Current: 7.6

0.4
22
Forward Rate of Return (Yacktman) 23.91
SRDX's Forward Rate of Return (Yacktman) is ranked higher than
75% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.70 vs. SRDX: 23.91 )
SRDX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 1.1   Max: 62.7
Current: 23.91

1.1
62.7

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
SurModics, Inc. was organized as a Minnesota corporation in June 1979. The Company is a provider of surface modification and in vitro diagnostic technologies to the healthcare industry. The Company's core offerings include surface modification coating technologies that impart lubricity, prohealing, and biocompatibility characteristics and components for in vitro diagnostic test kits and specialized surfaces for cell culture and microarrays. It partners with many of the emerging medical device, pharmaceutical and life science companies to develop and commercialize innovative products designed to improve patient outcomes. Although its drug delivery and surface modification technologies themselves are not directly regulated by the Food and Drug Administration, the medical devices, pharmaceutical and biotechnology products incorporating its technologies are subject to FDA regulation.
» More Articles for SRDX

Headlines

Articles On GuruFocus.com
SurModics Inc. Reports Operating Results (10-Q) Aug 06 2010 
SurModics Inc. Reports Operating Results (10-Q) May 07 2010 
SurModics Inc. Reports Operating Results (10-Q) Feb 05 2010 
SurModics Inc. Reports Operating Results (10-K) Dec 11 2009 
SurModics Inc. (SRDX) Senior VP & CFO Philip D Ankeny sells 5,000 Shares Oct 08 2009 
SurModics Inc. Reports Operating Results (10-Q) Aug 07 2009 
SurModics Inc. Reports Operating Results (10-Q) May 08 2009 
SurModics Inc. Reports Operating Results (10-Q) Feb 09 2009 
SurModics Reports First Quarter 2009 Results Jan 28 2009 
SurModics to Webcast Fiscal 2009 First Quarter Earnings Conference Call January 28 Jan 14 2009 

More From Other Websites
SurModics Announces Accelerated Share Repurchase Program Nov 12 2014
SURMODICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct... Nov 12 2014
SurModics Announces Accelerated Share Repurchase Program Nov 12 2014
SurModics Beats on Q4 Earnings, Issues Fiscal 2015 Outlook Nov 07 2014
SurModics tops Street 4Q forecasts Nov 07 2014
SurModics tops Street 4Q forecasts Nov 07 2014
SURMODICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Results of Operations... Nov 06 2014
SurModics Reports Fourth Quarter Fiscal 2014 Results Nov 06 2014
Q4 2014 SurModics Inc Earnings Release - After Market Close Nov 06 2014
SurModics to Webcast Fourth Quarter and Fiscal Year 2014 Earnings Conference Call on November 6 Oct 30 2014
SurModics to Webcast Fourth Quarter and Fiscal Year 2014 Earnings Conference Call on November 6 Oct 30 2014
SURMODICS INC Files SEC form 8-K, Change in Directors or Principal Officers Oct 08 2014
SurModics to Present at CL King's Best Ideas Conference Aug 26 2014
Time to Focus on SurModics (SRDX) for Strong Earnings Growth Potential Aug 18 2014
SURMODICS INC Financials Aug 08 2014
SurModics Beats on Earnings in Q3, Guidance Revised Aug 04 2014
SurModics (SRDX) in Focus: Stock Rises 6.6% in Session Aug 04 2014
SURMODICS INC Files SEC form 10-Q, Quarterly Report Aug 01 2014
SURMODICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Jul 31 2014
SurModics Reports Third Quarter Fiscal 2014 Results Jul 31 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK